<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=4423596&amp;fmt=gif">
Discover AGCellerate™ for LVV - a faster option to get your GMP-ready lentiviral vector product   Learn about AGCellerate

1 min read

AGC Biologics Copenhagen named Børsen Gazelle company for 2022

AGC Biologics Copenhagen named Børsen Gazelle company for 2022

The  Copenhagen site operates multiple mammalian and microbial cGMP manufacturing lines at a variety of scales, and the facility also offers a great depth of technological flexibility for projects ranging from pre-clinical through commercial production.

We are proud to announce that we were recognized as a Børsen Gazelle company for 2022! We were acknowledged for the work at our Copenhagen site, which operates multiple mammalian and microbial cGMP manufacturing lines at a variety of scales. This was celebrated at the award show in December 2022. 

"Since 1995, each year, the daily Børsen has identified Denmark’s growth elite and over time the gazelle has become part of the Danish language as a synonym for growing businesses. The selection is made by the Greens Institute of Market Research, the criteria are objective and based on data from the Danish Commerce and Companies Agency." - Børsen Awards Program

This award does not come easy, there are ambitious criteria that need to be met. According to the Børsen Awards Program, "receiving the title of Børsen Gazelle is an achievement that requires something out of the ordinary. A gazelle is a business that has achieved continuous growth in revenue or gross profit for the last four financial years, and in total, more than doubling the revenue or the gross profit in that period." 

As a growing company, this award shows the trust our customers place in us to bring their products to market. We deliver high-quality products and services to everyone who comes through our doors.  

Our core teams of scientists have strong scientific acumen and have been working together to develop and manufacture biologics for several decades. We are very proud of our expertise and experience, contributing to the growth of the company. This award acknowledges the hard work our employees put in every day to bring new products to market. 

To learn more about AGC Biologics’ mammalian and microbial system-based biologics manufacturing site in Seattle, visit www.agcbio.com/facilities/seattle. For more information on the company’s Protein Biologics, Protein DNA (pDNA), Cell Therapy, Viral Vector and Messenger RNA (mRNA) drug product services visit www.agcbio.com.